NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?

Key Takeaways NVO shares fell 10.2% in three months amid guidance cuts and weaker momentum for key GLP-1 drugs.Rising competition, slower Wegovy uptake and pricing pressure hit NVO's Q3, driving a second guidance cut.Novo Nordisk announced restructuring and a U.S. pricing deal as margin and execution risks mount.Novo Nordisk (NVO) shares have plunged 10.2% over three months as regulatory setbacks, a 2025 guidance cut, and softer demand for its blockbuster semaglutide-based (GLP-1) drugs, Ozempic (for type I ...